Zevra Therapeutics, Inc. ZVRA Return on equity

Return on equity at other companies

BioMarin PharmaceuticalsBMRN

9.1%+2.8pp

Ultragenyx PharmaceuticalRARE

-325.6%+36.9pp

RFL

Rafael Holdings, Inc.RFL

-26.6%-0.8pp

Rigel PharmaceuticalsRIGL

174.1%—

XER

Xeris Biopharma Holdings, Inc.XERS

-209.8%—

Theravance BiopharmaTBPH

50.2%+36.2pp

FAQ

What is Zevra Therapeutics, Inc.'s return on equity?

Zevra Therapeutics, Inc. (ZVRA) reported return on equity of 34.8% in Q2 2026.

How has Zevra Therapeutics, Inc.'s return on equity changed year-over-year?

Zevra Therapeutics, Inc.'s return on equity increased by 885.1% year-over-year, from 3.5% to 34.8%.

What is the long-term trend for Zevra Therapeutics, Inc.'s return on equity?

Over 2 years (2023 to 2025), Zevra Therapeutics, Inc.'s return on equity has grown at a 12.9% compound annual growth rate (CAGR), from -67.2% to 85.7%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.